Key Points
- Insider sale: Eton Pharmaceuticals insider David Krempa sold 19,679 shares on May 27 at an average price of $31.47, totaling about $619,298. The sale reduced his ownership by 43.8%.
- Recent selling streak: Krempa also sold shares on May 22 and May 26, bringing his recent total sales to more than 99,000 shares over three transactions. Those earlier sales were worth about $1.43 million and $1.18 million, respectively.
- Company snapshot: Eton opened at $32.40, near its 52-week high of $35.66, and recently reported quarterly EPS of $0.05, missing estimates while revenue came in above expectations. Analysts currently have a consensus Hold rating with an average price target of $41.00.
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 19,679 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the transaction, the insider directly owned 25,249 shares in the company, valued at $794,586.03. The trade was a 43.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
David Krempa also recently made the following trade(s):
- On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83.
- On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total value of $1,181,630.76.
Eton Pharmaceuticals Price Performance
NASDAQ ETON opened at $32.40 on Thursday. The business's fifty day moving average price is $26.59 and its 200-day moving average price is $20.03. The stock has a market capitalization of $887.44 million, a price-to-earnings ratio of -462.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. Eton Pharmaceuticals, Inc. has a 1-year low of $13.09 and a 1-year high of $35.66.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. On average, equities analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 earnings per share for the current year.
Hedge Funds Weigh In On Eton Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Soleus Capital Management L.P. purchased a new stake in Eton Pharmaceuticals in the 2nd quarter worth $4,061,000. Millennium Management LLC increased its stake in Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after buying an additional 217,042 shares in the last quarter. Oberweis Asset Management Inc. purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth $4,180,000. Lumbard & Kellner LLC purchased a new stake in Eton Pharmaceuticals in the 3rd quarter worth $3,831,000. Finally, BNP Paribas Financial Markets increased its stake in Eton Pharmaceuticals by 162.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company's stock worth $4,993,000 after buying an additional 142,094 shares in the last quarter. 27.86% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Craig Hallum raised their target price on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, March 20th. HC Wainwright raised their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a "buy" rating in a report on Friday, May 15th. B. Riley Financial raised their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, March 20th. Wall Street Zen raised Eton Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, March 21st. Finally, Zacks Research cut Eton Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $41.00.
Check Out Our Latest Stock Report on Eton Pharmaceuticals
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
